Validation of Progranulin as a Biomarker for Sepsis

Ludwig-Maximilians - University of Munich556 enrolled

Overview

Progranulin blood concentrations in patients with sepsis will be analysed in relation to disease status in order to validate progranulin as a biomarker for sepsis. Patients undergoing cardiac surgery will serve as controls.

Single nucleotide polymorphisms with known effects on Progranulin plasma concentrations will be assessed in a separate analysis. Expression levels of microRNAs isolated from plasma, circulating exosomes and blood cells will be determined by next-generation sequencing to characterize epigenetic influences on progranulin plasma levels.

Study Type

OBSERVATIONAL

Enrollment

556

Conditions

Sepsis

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Sepsis or Septic Shock defined according to SEPSIS-3 criteria - Age \> 18 years Exclusion Criteria: * No informed consent * Age \< 18 years * Pregnancy * Immunosuppression (including transplantation) * Charlson Comorbidity Index \> 0 (healthy volunteers)

Locations (2)

Department of Anesthesiology, LMU Munich

Munich, Bavaria, Germany

Department of Anesthesiology, Klinikum Neuperlach

Munich, Bavaria, Germany

Outcomes

Primary Outcomes

Change in progranulin plasma concentrations during ICU - therapy

Blood samples will be taken at the abovementioned time points

Time frame: ICU admission, day 1, day 4 of ICU therapy

Secondary Outcomes

Change in miRNA expression levels in exosomes, serum and blood cells during ICU - therapy

Blood samples will be taken at the abovementioned time points

Time frame: ICU admission, day 1, day 4 of ICU therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.